J. Labenz

发表

Management of reflux esophagitis: does the choice of proton pump inhibitor matter?

A. Leodolter, D. Armstrong, J. Labenz, 2015, International journal of clinical practice.

Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis – results from the EXPO study

A. Leodolter, D. Armstrong, S. Zetterstrand, 2009, Alimentary pharmacology & therapeutics.

Efficacy of Esomeprazole (20 mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin

C. Hawkey, Á. Lanas, S. V. Zanten, 2008, The American Journal of Gastroenterology.

ORIGINAL CONTRIBUTIONS Stomach Efficacy of Esomeprazole (20 mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin

C. Hawkey, Á. Lanas, S. V. Zanten, 2008 .

Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus

P. Malfertheiner, S. Willich, M. Vieth, 2006, Alimentary pharmacology & therapeutics.

Prospective Follow-Up Data from the ProGERD Study Suggest that GERD Is Not a Categorial Disease

P. Malfertheiner, S. Willich, M. Vieth, 2006, The American Journal of Gastroenterology.

Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study 1

K. Lauritsen, P. Katelaris, K. Schütze, 2005, Alimentary pharmacology & therapeutics.

Treatment of uncomplicated reflux disease.

P. Malfertheiner, J. Labenz, 2005, World journal of gastroenterology.

Prognostic influence of Barrett’s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study

P. Malfertheiner, S. Willich, M. Vieth, 2005, Gut.

Esomeprazole: potent acid suppression in the treatment of acid-related disorders

S. Miehlke, K. Petersen, J. Labenz, 2005, Expert review of clinical immunology.

A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study

K. Lauritsen, P. Katelaris, K. Schütze, 2005, Alimentary pharmacology & therapeutics.

What Parameters Are Relevant for the Histological Diagnosis of Gastroesophageal Reflux Disease without Barrett’s Mucosa?

P. Malfertheiner, S. Willich, M. Vieth, 2004, Digestive Diseases.

An update on the available treatments for non-erosive reflux disease

J. Labenz, A. Morgner-Miehlke, 2006, Expert opinion on pharmacotherapy.

Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study.

A. Blum, J. Labenz, U. Peitz, 1997, Gut.

Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers

S. Miehlke, A. Morgner, J. Labenz, 2007, Expert opinion on pharmacotherapy.

Consequences of Helicobacter pylori cure in ulcer patients.

J. Labenz, Joachim Labenz, 2000, Bailliere's best practice & research. Clinical gastroenterology.

Work satisfaction and burnout risk of gastroenterologists in Germany: results of a nationwide survey

U. Beilenhoff, C. Adarkwah, J. Labenz, 2020, Zeitschrift für Gastroenterologie - German Journal of Gastroenterology.

Does Helicobacter pylori Affect the Management of Gastroesophageal Reflux Disease?

J. Labenz, 1999, American Journal of Gastroenterology.

S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit

P. Malfertheiner, M. Selgrad, S. Suerbaum, 2016, Zeitschrift für Gastroenterologie.

Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection.

J. Labenz, G. Börsch, 1994, The American journal of gastroenterology.

Facts and fantasies in extra-oesophageal symptoms in GORD.

J. Labenz, 2010, Best practice & research. Clinical gastroenterology.

NSAID-Associated Dyspepsia and Ulcers: A Prospective Cohort Study in Primary Care

M. Stolte, A. Leodolter, J. Labenz, 2006, Digestive Diseases.

Diagnostic of Helicobacter pylori infection

F. Mégraud, P. Floch, P. Lehours, 2016, Helicobacter.

PROTAGONIST Should we eradicate Helicobacter pylori before long term antireflux therapy ?

J. Labenz, 2001 .

Should we eradicate Helicobacter pylori before long term antireflux therapy

J. Labenz, 2001 .

Effective regimens for the treatment of Helicobacter pylori infection

S. Miehlke, A. Morgner, J. Labenz, 2006, Expert opinion on investigational drugs.

High rate of post‐therapeutic resistance after failure of macrolide–nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second‐line therapies in a randomized study

P. Malfertheiner, M. Stolte, A. Leodolter, 2002, Alimentary pharmacology & therapeutics.

Diagnostic Accuracy of 13C-Urea Breath Test in the Diagnosis of Helicobacter pylori Infection in Patients with Partial Gastric Resection due to Peptic Ulcer Disease

M. Stolte, R. Jakobs, D. Schilling, 2001, Digestion.

[Insufficient validity of a rapid blood test for diagnosis of Helicobacter pylori infection].

P. Malfertheiner, M. Stolte, J. Labenz, 2001, Medizinische Klinik.

One‐week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease

K. Lauritsen, S. Veldhuyzen van Zanten, T. Lind, 2000, Alimentary pharmacology & therapeutics.

Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse.

J. Labenz, G. Börsch, Joachim Labenz, 1994, Digestion.

Long-term consequences of Helicobacter pylori eradication: clinical aspects.

J. Labenz, U. Peitz, B. Tillenburg, 1996, Scandinavian journal of gastroenterology. Supplement.

[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori].

M. Stolte, J. Labenz, U. Peitz, 1995, Leber, Magen, Darm.

One-week low-dose triple therapy for the eradication of Helicobacter pylori infection.

M. Stolte, J. Labenz, B. Tillenburg, 1995, European journal of gastroenterology & hepatology.

The epidemiology, diagnosis, and treatment of Barrett's carcinoma.

R. Kiesslich, A. Hölscher, A. Tannapfel, 2015, Deutsches Arzteblatt international.

Outcomes of different treatment opproaches for gastro-oesophageal reflux disease

J. Labenz, 2008 .

Burnout and work satisfaction are differentially associated in gastroenterologists in Germany.

C. Adarkwah, J. Labenz, Oliver Hirsch, 2022, F1000Research.

Treatment of uncomplicated reflux disease.

P. Malfertheiner, J. Labenz, 2005, World journal of gastroenterology.

Gastro esophageal reflux disease is associated with absence from work: results from a prospective cohort study.

P. Malfertheiner, S. Willich, A. Leodolter, 2005, World journal of gastroenterology.

Helicobacter pylori eradication leads to gastro-oesophageal reflux disease

J. Labenz, 2003 .

Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?

P. Malfertheiner, J. Labenz, 1997, Gut.

Management of hepatic encephalopathy in Germany: a survey among physicians

P. Galle, T. Frieling, C. Labenz, 2020, Zeitschrift für Gastroenterologie.

Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis.

P. Galle, J. Schattenberg, C. Labenz, 2020, European journal of internal medicine.

Epidemiology of hepatic encephalopathy in german hospitals – the EpHE study

P. Galle, J. Schattenberg, C. Labenz, 2017, Zeitschrift für Gastroenterologie.

A summary of Food and Drug Administration‐reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole

K. Petersen, J. Labenz, W. Rösch, 2003, Alimentary pharmacology & therapeutics.

Inhibition of the herpes simplex virus-coded thymidine kinase-complex by 9-β-D-arabinofuranosyladenine 5′-monophosphate (ara-AMP) and 9-(2-hydroxyethoxymethyl)guanine-monophosphate (acyclo-GMP)

W. Müller, D. Falke, J. Labenz, 2005, Archives of Virology.

Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole.

A. Blum, M. Stolte, D. Armstrong, 1995, Gut.

Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer.

A. Blum, M. Stolte, E. Verdu, 1996, Gastroenterology.

Correlation of serum pepsinogens and gastrin‐17 with atrophic gastritis in gastroesophageal reflux patients: A matched‐pairs study

P. Malfertheiner, S. Willich, M. Vieth, 2011, Journal of gastroenterology and hepatology.

Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies

J. Schattenberg, C. Labenz, J. Marquardt, 2020, Zeitschrift für Gastroenterologie.

Best Practice & Research Clinical Gastroenterology

J. Labenz, 2010 .

Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study.

P. Malfertheiner, S. Willich, M. Vieth, 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prevalence of extra‐oesophageal manifestations in gastro‐oesophageal reflux disease: an analysis based on the ProGERD Study

P. Malfertheiner, S. Willich, M. Vieth, 2003, Alimentary pharmacology & therapeutics.

Evidence for the essential role of Helicobacter pylori in gastric ulcer disease.

J. Labenz, G. Börsch, 1994, Gut.

Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis

P. Galle, J. Schattenberg, C. Labenz, 2019, The American journal of gastroenterology.

[S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013].

H. Messmann, S. Miehlke, K. Fuchs, 2014, Zeitschrift fur Gastroenterologie.

[Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)].

J. Trebicka, A. Gerbes, R. Wiest, 2019, Zeitschrift fur Gastroenterologie.

Colonoscopy in Acute Diverticulitis

R. Kiesslich, A. Eckardt, J. Labenz, 2015, Visceral Medicine.

Endoscopic Procedures in Patients under Clopidogrel or Dual Antiplatelet Therapy: A Survey among German Gastroenterologists and Current Guidelines

L. Theilmann, J. Labenz, A. Abdel Samie, 2014, Zeitschrift für Gastroenterologie.

Application of a multispecies probiotic reduces gastro-intestinal discomfort and induces microbial changes after colonoscopy

I. Klymiuk, V. Stadlbauer, A. Horvath, 2022, Frontiers in Oncology.

Management of functional dyspepsia: Unsolved problems and new perspectives.

S. Miehlke, J. Labenz, A. Madisch, 2005, World journal of gastroenterology.

The Diagnosis and Treatment of Functional Dyspepsia.

P. Enck, T. Frieling, M. Schemann, 2018, Deutsches Arzteblatt international.

EndoStim®-Therapie – eine neue minimal-invasive Technologie in der Antirefluxchirurgie

J. Labenz, D. Stephan, S. Attwood, 2018, Der Chirurg.

Analysis of the TK enzyme complex induced by HSV types 1 and 2 by means of isoelectric focusing and polyacrylamide gel electrophoresis

D. Falke, J. Labenz, D. Friedrich, 2005, Archives of Virology.

[Chronic abdominal pain: these diseases can be the cause].

C. Labenz, J. Labenz, M. Gross, 2015, Deutsche medizinische Wochenschrift.

Prevalence and pattern of Helicobacter pylori gastritis in the gastric cardia.

P. Malfertheiner, A. Roessner, J. Labenz, 1997, The American journal of gastroenterology.

Helicobacter pylori increases the risk of peptic ulcer bleeding: a case-control study.

P. Malfertheiner, J. Labenz, U. Peitz, 1999, Italian journal of gastroenterology and hepatology.

German guideline diverticular disease/diverticulitis

J. Ritz, J. Keller, F. Dumoulin, 2022, United European gastroenterology journal.

[Diagnosis and therapy of Helicobacter pylori infection. Guidelines of the German Society of Digestive and Metabolic Diseases].

P. Malfertheiner, M. Stolte, B. Braden, 1996, Zeitschrift fur Gastroenterologie.

Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success.

J. Labenz, G. Börsch, F. Leverkus, 1994, Scandinavian journal of gastroenterology.

Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study.

J. Labenz, G. Börsch, G. Rühl, 1993, Gut.

High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease.

M. Stolte, C. Domian, J. Labenz, 1995, Digestion.

7-day triple therapy with esomeprazole, amoxicillin and clarithromycin for H. pylori (Hp) eradication in duodenal ulcer (DU) disease

K. Lauritsen, T. Lind, J. Labenz, 2000 .

S3-Leitlinie „Helicobacter pylori und gastroduodenale Ulkuskrankheit” der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)

P. Malfertheiner, S. Suerbaum, U. Rosien, 2009, Zeitschrift fur Gastroenterologie.

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.

A. Blum, C. O'Morain, Á. Theodórs, 1998, The New England journal of medicine.

Serum gastrin and pepsinogens do not correlate with the different grades of severity of gastro‐oesophageal reflux disease: a matched case–control study

P. Malfertheiner, M. Vieth, M. Stolte, 2008, Alimentary pharmacology & therapeutics.

[Current value of quinolones in Helicobacter pylori therapy].

S. Miehlke, A. Morgner, J. Labenz, 2011, Zeitschrift fur Gastroenterologie.

S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease

P. Malfertheiner, M. Selgrad, S. Suerbaum, 2016, Zeitschrift für Gastroenterologie.

Current role of acid suppressants in Helicobacter pylori eradication therapy.

J. Labenz, J. Labenz, 2001, Best practice & research. Clinical gastroenterology.

[Qualitative and semiquantitative invasive and noninvasive diagnosis of Helicobacter pylori colonization of gastric mucosa].

M. Stolte, J. Labenz, J. Bertrams, 1993, Zeitschrift fur Gastroenterologie.

Proton pump inhibitor use is associated with a variety of infections in patients with liver cirrhosis

P. Galle, K. Kostev, C. Labenz, 2020, Medicine.

Effect of curing Helicobacter pylori (HP) infection on intragastric pH during omeprazole treatment

A. Blum, M. Stolte, D. Armstrong, 1995 .

Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis.

A. Blum, M. Stolte, E. Bayerdörffer, 1997, Gastroenterology.

Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer.

A. Blum, M. Stolte, J. Labenz, 1997, Gut.

The “Aachen sings” study (“Aachen choir engagement study into GERD symptoms”): moderate singing and breathing exercises in a choir reduce reflux symptoms – a cohort study in non-specialist choristers

K. Streetz, C. Dietrich, J. Labenz, 2019, Zeitschrift für Gastroenterologie.

Progression of specialized intestinal metaplasia at the cardia to macroscopically evident Barrett's esophagus: an entity of concern in the ProGERD study

P. Malfertheiner, S. Willich, M. Vieth, 2012, Scandinavian journal of gastroenterology.

German guideline diverticular disease/diverticulitis

A. Schreyer, J. Ritz, J. Keller, 2022, United European gastroenterology journal.

[S2k guidelines diverticular disease/diverticulitis].

C. Germer, T. Sauerbruch, J. Ritz, 2014, Zeitschrift fur Gastroenterologie.

Kapitel 4 – Gastroenterologie

J. Labenz, J. Labenz, 2017 .

Ulcers: Adjuvant PPIs to prevent major ulcer bleeds

A. Leodolter, J. Labenz, 2009, Nature Reviews Gastroenterology &Hepatology.

Submucosal Fibrin Adhesion in Upper Gastrointestinal Bleeding

J. Labenz, U. Peitz, G. Börsch, 1994 .

Balanced perspective essential in erosive oesophagitis treatment: Author's reply

J. Labenz, 2005 .

[Diverticular bleeding. Diagnostics, non-surgical treatment, indications for surgery].

J. Labenz, 2014, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

Impact of S3 Training Courses “Sedation and Emergency Management in Endoscopy for Endoscopy Nurses and Assisting Personnel” on the Process and Structure Quality in Gastroenterological Endoscopy in Practices and Clinics – Results of a Nationwide Survey

A. Riphaus, D. Schilling, U. Beilenhoff, 2013, Zeitschrift für Gastroenterologie.

Focal Inflammatory Infiltrations in Gastric Biopsy Specimens Are Suggestive of Crohn's Disease

M. Stolte, E. Bayerdörffer, C. Thiede, 1997 .

Helicobacter pylori re-infection and clinical course of peptic ulcer disease in the first year post-amoxicillin/omeprazole treatment

J. Labenz, G. Börsch, G. Rühl, 1992 .

[Diagnosis of Helicobacter pylori colonization of the gastric mucosa. A prospective comparative study of direct test methods and validation of a new urease test].

J. Labenz, U. Peitz, G. Börsch, 1991, Medizinische Klinik.

ulcer patients with omeprazole and amoxicillin

A. Blum, M. Stolte, J. Labenz, 2006 .

Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease

J. Labenz, J. Bertrams, G. Börsch, 1994, Alimentary pharmacology & therapeutics.

One‐week low‐dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers

J. Labenz, U. Peitz, B. Tillenburg, 1997, Alimentary pharmacology & therapeutics.

One‐week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection

M. Stolte, J. Labenz, U. Peitz, 1996, Alimentary pharmacology & therapeutics.

Intragastric acidity during administration of generic omeprazole or esomeprazole – a randomised, two‐way crossover study including CYP2C19 genotyping

S. Miehlke, A. Morgner, J. Labenz, 2011, Alimentary pharmacology & therapeutics.

Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two‐way crossover study

S. Miehlke, A. Morgner, J. Labenz, 2005, Alimentary pharmacology & therapeutics.

Barrett-Ösophagus

J. Labenz, Prof. Dr. med. J. Labenz, 2016, Der Internist.

Nighttime Heartburn in Patients with Gastroesophageal Reflux Disease under Routine Care

P. Malfertheiner, S. Willich, M. Vieth, 2008, Digestion.

P. Malfertheiner, M. Vieth, A. Leodolter, 2009, Alimentary pharmacology & therapeutics.

Clinical management of eosinophilic esophagitis – a nationwide survey among gastroenterologists in Germany

T. Frieling, C. Schlag, S. Miehlke, 2019, Zeitschrift für Gastroenterologie.

Management of eosinophilic esophagitis associated food impaction in Europe and the United States.

Joy W. Chang, A. Bredenoord, A. Schoepfer, 2022, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[Bleeding gastric and duodenal varicose veins: endoscopic embolisation using tissue adhesives].

J. Labenz, G. Börsch, 2008, Deutsche Medizinische Wochenschrift.

Gastritis: Update 2020

A. Tannapfel, H. Koop, J. Labenz, 2020, Gastroenterologie up2date.

Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori.

J. Labenz, G. Börsch, G. Rühl, 1993, The American journal of gastroenterology.

Validity of a novel biopsy urease test (HUT) and a simplified 13C-urea breath test for diagnosis of Helicobacter pylori infection and estimation of the severity of gastritis.

M. Stolte, J. Labenz, U. Peitz, 1996, Digestion.

Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin.

A. Blum, M. Stolte, J. Labenz, 1995, Gut.

Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study).

P. Malfertheiner, M. Stolte, J. Läuter, 2001, World journal of gastroenterology.

Evolution of gastro‐oesophageal reflux disease over 5 years under routine medical care – the ProGERD study

P. Malfertheiner, S. Willich, M. Vieth, 2012, Alimentary pharmacology & therapeutics.

UEGW-Update

J. Labenz, R. Kiesslich, 2010, Der Gastroenterologe.

Psychometric validation of the German translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in patients with reflux disease

P. Malfertheiner, I. Wiklund, S. Miehlke, 2003, Health and quality of life outcomes.

[Oral triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease].

J. Labenz, G. Börsch, G. Rühl, 1993, Medizinische Klinik.

Lack of Effect of TreatingHelicobacter pyloriInfection in Patients with Nonulcer Dyspepsia

A. Blum, C. O'Morain, Á. Theodórs, 1998 .

Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study.

P. Malfertheiner, S. Willich, M. Vieth, 2004, Journal of clinical epidemiology.

[Biliary diseases in the elderly: diagnosis and therapy].

J. Labenz, 1993, Zeitschrift fur Gerontologie.

Successful endoscopic hemostasis of duodenal variceal bleeding with histoacryl.

J. Labenz, G. Börsch, 1993, Endoscopy.

Cost‐of‐disease analysis in patients with gastro‐oesophageal reflux disease and Barrett's mucosa

P. Malfertheiner, M. Stolte, M. Nocon, 2006, Alimentary pharmacology & therapeutics.

Risk Factors for Erosive Esophagitis: A Multivariate Analysis Based on the ProGERD Study Initiative

P. Malfertheiner, S. Willich, M. Stolte, 2004, The American Journal of Gastroenterology.

Raised serum Interleukin‐6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy

P. Galle, J. Schattenberg, C. Labenz, 2019, Alimentary pharmacology & therapeutics.

Quality of life in relation to symptoms in patients with gastro‐oesophageal reflux disease — an analysis based on the ProGERD initiative

P. Malfertheiner, S. Willich, M. Vieth, 2003, Alimentary pharmacology & therapeutics.

Work satisfaction and risk of burnout for endoscopy staff in Germany: Results of a nationwide survey

U. Beilenhoff, C. Adarkwah, J. Labenz, 2021, Zeitschrift für Gastroenterologie.

Burnout and work satisfaction in general practitioners practicing in rural areas: results from the HaMEdSi study

A. Becker, C. Adarkwah, J. Labenz, 2018, Psychology research and behavior management.

Does Helicobacter pylori status affect nonsteroidal anti-inflammatory drug-associated gastroduodenal pathology?

P. Malfertheiner, J. Labenz, 1998, The American journal of medicine.

GPs’ motivation for teaching medical students in a rural area—development of the Motivation for Medical Education Questionnaire (MoME-Q)

A. Becker, C. Adarkwah, J. Labenz, 2019, PeerJ.

[Bowel cleansing prior to colonoscopy. A prospective, randomized, blind comparative study].

J. Labenz, G. Börsch, F. Leverkus, 1990, Medizinische Klinik.

Impact of reflux disease on general and disease-related quality of life - evidence from a recent comparative methodological study in Germany.

P. Malfertheiner, I. Wiklund, S. Miehlke, 2003, Zeitschrift fur Gastroenterologie.

How effective are PPIs for the treatment of patients with peptic ulcer bleeding?

A. Morgner, J. Labenz, 2007, Nature Clinical Practice Gastroenterology &Hepatology.

Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy.

J. Labenz, M. Freitag, W. Opferkuch, 1994, The American journal of gastroenterology.

Primary prophylaxis of NSAID-induced gastroduodenal ulcers and dyspepsia in H. pylori (HP)-positive patients: Randomized, double-blind, placebo-controlled treatment of HP infection VS. omeprazole

A. Blum, M. Stolte, J. Labenz, 2000 .

Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“

J. Trebicka, A. Gerbes, R. Wiest, 2019, Zeitschrift für Gastroenterologie.

Holistic management of symptomatic reflux: rising to the challenge of proton pump inhibitor overuse

E. Savarino, J. Labenz, J. Mendive, 2022, The British journal of general practice : the journal of the Royal College of General Practitioners.

Holistic management of symptomatic reflux: rising to the challenge of proton pump inhibitor overuse

E. Savarino, J. Labenz, J. Mendive, 2022, The British journal of general practice : the journal of the Royal College of General Practitioners.

Lifestyle factors and symptoms of gastro‐oesophageal reflux – a population‐based study

S. Willich, M. Nocon, J. Labenz, 2006, Alimentary pharmacology & therapeutics.

[Gastro-Oesophageal Reflux Disease - How to Manage if PPI are not Sufficiently Effective, not Tolerated, or not Wished?]

H. Koop, J. Labenz, 2018, Laryngo- rhino- otologie.

[S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease].

P. Malfertheiner, M. Selgrad, S. Suerbaum, 2016, Zeitschrift fur Gastroenterologie.

Proposed approach to the challenging management of progressive gastroesophageal reflux disease

T. Demeester, P. Chandrasoma, J. Labenz, 2018, World journal of gastrointestinal endoscopy.

Effectiveness of Menthacarin on symptoms of irritable bowel syndrome

S. Miehlke, B. Stracke, S. Köhler, 2018, Wiener Medizinische Wochenschrift.

Long-term clinical course of ulcer disease and incidence of reflux esophagitis in a large cohort of duodenal ulcer patients followed after eradication of Helicobacter pylori

M. Stolte, J. Labenz, U. Peitz, 1995 .

S3-guideline "helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF

J. Bornschein, P. Malfertheiner, S. Suerbaum, 2009, Zeitschrift fur Gastroenterologie.

Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial

A. Blum, M. Stolte, J. Labenz, 2002, Gut.

[Ciprofloxacin-omeprazole combination therapy for eradication of Helicobacter pylori].

J. Labenz, U. Peitz, G. Börsch, 1991, Zeitschrift fur Gastroenterologie.

[Extraesophageal manifestations of gastroesophageal reflux disease: a critical analysis].

J. Labenz, 2009, Deutsche Medizinische Wochenschrift.

A celebration of British gastroenterology, 1987-97

J. Labenz, E. Gyenes, G. H. Riihl, 2022 .

Validation of the Clinical Frailty Scale for the Prediction of Mortality in Patients With Liver Cirrhosis

P. Galle, C. Labenz, M. Wörns, 2020, Clinical and translational gastroenterology.

Bleeding watermelon stomach treated by Nd-YAG laser photocoagulation.

J. Labenz, G. Börsch, 1993, Endoscopy.

Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis ‐ results from the maintenance phase of the EXPO study

A. Leodolter, D. Armstrong, S. Zetterstrand, 2009, Alimentary pharmacology & therapeutics.

Association of body mass index with heartburn, regurgitation and esophagitis: Results of the Progression of Gastroesophageal Reflux Disease study

P. Malfertheiner, S. Willich, M. Stolte, 2007, Journal of gastroenterology and hepatology.

Letter to the editor: Evidence on the use of l‐ornithine l‐aspartate in overt HE—But does it really improve prognosis?

P. Galle, C. Labenz, J. Labenz, 2021, Hepatology.

Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease.

J. Labenz, J. Bertrams, G. Börsch, 1994, The American journal of gastroenterology.

Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis.

A. Blum, M. Stolte, D. Armstrong, 1996, Scandinavian journal of gastroenterology.

Clinical course of laryngo‐respiratory symptoms in gastro‐oesophageal reflux disease during routine care ‐ a 5‐year follow‐up

P. Malfertheiner, M. Vieth, M. Stolte, 2009, Alimentary pharmacology & therapeutics.

Long‐term treatment of patients with gastro‐oesophageal reflux disease in routine care – results from the ProGERD study

P. Malfertheiner, M. Stolte, M. Nocon, 2007, Alimentary pharmacology & therapeutics.

Increased risk for Helicobacter pylori recurrence by continuous acid suppression: a randomized controlled study.

P. Malfertheiner, G. Manes, J. Dominguez-Munoz, 1998, Italian journal of gastroenterology and hepatology.

Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.

M. Stolte, J. Labenz, U. Peitz, 1995, Zeitschrift fur Gastroenterologie.

Diagnostic accuracy of (13)C-urea breath test in the diagnosis of Helicobacter pylori infection in patients with partial gastric resection due to peptic ulcer disease: a prospective multicenter study.

M. Stolte, R. Jakobs, D. Schilling, 2001, Digestion.

Two weeks treatment with amoxicillin/omeprazole for eradication of Helicobacter pylori.

J. Labenz, G. Börsch, G. Rühl, 1992, Zeitschrift fur Gastroenterologie.

Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers.

J. Labenz, G. Börsch, 1995, The American journal of gastroenterology.

Ciprofloxacin-Omeprazole Treatment for Eradication of Helicobacter pylori

J. Labenz, U. Peitz, G. Börsch, 1993 .

Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients.

A. Blum, M. Stolte, J. Labenz, 1997, The American journal of gastroenterology.

Esomeprazole therapy improves sleep disorders in patients with gastroesophageal reflux disease (GERD): A report from the ProGerd study

P. Malfertheiner, S. Willich, M. Vieth, 2003 .

Efficacy and tolerability of a one‐week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer

M. Stolte, J. Weismüller, J. Labenz, 1997, Alimentary pharmacology & therapeutics.

Clinical course of duodenal ulcer disease one year after omeprazole plus amoxycillin or triple therapy plus ranitidine for cure of Helicobacter pylori infection

J. Labenz, J. Bertrams, G. Börsch, 1994 .

Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients

J. Labenz, C. Dekkers, H. Klör, 1997, Alimentary pharmacology & therapeutics.

[Helicobacter pylori: pretherapeutic resistance status in Germany (Ruhr area)].

J. Labenz, U. Peitz, B. Tillenburg, 1997, Zeitschrift für Gastroenterologie - German Journal of Gastroenterology.

Modified Helicobacter test using a new test meal and a 13C-urea breath test in Helicobacter pylori positive and negative dyspepsia patients on proton pump inhibitors

P. Malfertheiner, J. Labenz, S. Aygen, 2017, World journal of gastroenterology.

Proton Pump Inhibitors in Patients With Liver Cirrhosis: Evidence to Improve Their Battered Reputation.

C. Labenz, J. Labenz, 2021, American Journal of Gastroenterology.

Response to Professor Quigley's Letter

J. Labenz, 2007, The American Journal of Gastroenterology.

Menthacarin, a Proprietary Peppermint Oil and Caraway Oil Combination, Improves Multiple Complaints in Patients with Functional Gastrointestinal Disorders: A Systematic Review and Meta-Analysis

T. Frieling, S. Miehlke, B. Stracke, 2022, Digestive Diseases.

Therapie der Helicobacter-pylori-Infektion*

J. Labenz, G. Börsch, 2008 .

[How safe is sedation in gastrointestinal endoscopy? A multicentre analysis of 388,404 endoscopies and analysis of data from prospective registries of complications managed by members of the Working Group of Leading Hospital Gastroenterologists (ALGK)].

A. Behrens, C. Ell, F. Dumoulin, 2013, Zeitschrift fur Gastroenterologie.

Medium- and high-dose omeprazole plus amoxicillin for eradication ofHelicobacter pylori in duodenal ulcer disease

J. Labenz, J. Bertrams, G. Börsch, 1994, Digestive Diseases and Sciences.

Kapitel 4 – Gastroenterologie

J. Labenz, 2017 .

S 2 k-Guideline Helicobacter pylori and gastroduodenal ulcer disease 1 S 2 k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit

P. Malfertheiner, M. Selgrad, S. Suerbaum, 2017 .

Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“

J. Trebicka, A. Gerbes, A. Schreyer, 2019, Zeitschrift für Gastroenterologie.

Duale antithrombozytäre Therapie – Perioperativ absetzen oder weiterführen?

E. Giannitsis, U. Zeymer, M. Spannagl, 2017, DMW - Deutsche Medizinische Wochenschrift.

Cardiac Magnetic Resonance Imaging Using an Open 0.35 T System

H. Klein, J. Labenz, W. Meyners, 2007, Journal of computer assisted tomography.

The Diagnosis and Treatment of Functional Dyspepsia.

P. Enck, T. Frieling, M. Schemann, 2018, Deutsches Arzteblatt international.

Alginat bei Bedarf als Add-on bei unzureichendem Effekt von Protonenpumpen-Hemmern bei Patienten mit gastroösophagealer Reflux-Krankheit

J. Labenz, D. Borkenstein, Matthias Müller, 2018, DMW - Deutsche Medizinische Wochenschrift.

Modified Helicobacter test using a new test meal and a 13C-urea breath test in Helicobacter pylori positive and negative dyspepsia patients on proton pump inhibitors

P. Malfertheiner, J. Labenz, S. Aygen, 2017, World journal of gastroenterology.

Chronischer Oberbauchschmerz: Diese organische Erkrankungen können die Ursache sein

M. Gross, J. Labenz, J. Labenz, 2015, DMW Deutsche Medizinische Wochenschrift.

[Ulcer healing through the elimination of Helicobacter pylori: is a week of therapy enough?].

M. Stolte, J. Labenz, U. Peitz, 1996, Deutsche medizinische Wochenschrift.

Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin.

A. Blum, M. Stolte, J. Labenz, 1995, Gut.